HLA-C and neoplasm: Li et al. integrated MRI scans, the presence of genomic biomarkers (immunophenoscore-associated mRNAs, MHC-related molecules, immune checkpoints, immunomodulators, and suppressor cells) and clinical data (age, gender, treatment type, and tumor grade) to calculate a risk score predictive of a patient’s response to immunotherapy [28].